7.4800
17-May-24 11:29:46
15 minutes delayed
Stocks
-0.0600
-0.80%
Today's range
7.4600 - 7.6700
ISIN
FR0012127173
Source
Cboe
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
16 Apr 2024 12:00:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
10 Apr 2024 12:00:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
02 Apr 2024 01:30:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
27 Mar 2024 13:00:00 By Nasdaq GlobeNewswire